EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

The European Medicines Agency authorised Vanflyta (quizartinib dihydrochloride) from Daiichi Sankyo Europe GmbH for the treatment of acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VANFLYTA (quizartinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Daiichi Sankyo Europe GmbH. Decision date: 03/02/2026